ClinicalTrials.gg
RecruitingNCT07192783Updated Sep 25, 2025

The Effect of Lavender Inhalation on Anxiety, Sleep, and Blood Pressure

An interventional study of Lavender in Primary Hypertension, sponsored by Ardahan University. Recruiting at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Ardahan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Essential Hypertension with a site in Turkey — 6 open to participants now, 6 under way, none of them phase 3. Essential Hypertension · Turkey.

Planned enrollment
16th of 19
50 · median 130
Started
2025
with 1 other
No phase
11 of 21
5 open now
Registered
16th of 21
by date
Lead sponsor
1 of 21
Ardahan University

Among the 21 studies in Essential Hypertension with a site in Turkey, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 16th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

6 of the 21 studies in Essential Hypertension with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Essential Hypertension with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to determine the effects of lavender oil inhalation on anxiety, sleep quality, and blood pressure in patients with primary hypertension. The study is designed as a double-blind randomized controlled trial. The study population consists of patients presenting to the Cardiology Outpatient Clinic of Ardahan State Hospital. Participants are randomly assigned to an experimental group, which will receive a total of 12 lavender oil inhalations three times a week for one month, or to a control group, which will continue routine treatment and care. Data will be collected using the Hypertension Diagnostic Form, Beck Anxiety Inventory, and Pittsburgh Sleep Quality Index. Statistical analyses will be conducted to compare outcomes between the experimental and control groups.

Read the detailed description

This study aims to evaluate the effects of lavender oil inhalation on anxiety, sleep quality, and blood pressure in patients with primary hypertension. It is designed as a double-blind randomized controlled trial. Patients presenting to the Cardiology Outpatient Clinic of Ardahan State Hospital will be recruited for the study. Participants will be randomly assigned to an experimental group, which will receive 12 lavender oil inhalations three times a week for one month, or to a control group, which will continue routine care. Data will be collected using the Hypertension Diagnostic Form, Beck Anxiety Inventory, and Pittsburgh Sleep Quality Index. The study will assess whether lavender oil inhalation affects anxiety, sleep quality, and blood pressure in this population. Statistical analyses will be conducted to compare outcomes between the experimental and control groups.

03

Conditions studied

  • Primary Hypertension

Keywords

  • primary hypertension
  • anxiety
  • sleep quality
  • blood pressure
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with primary hypertension
  • Willing to participate in the study
  • No allergy to lavender
  • No olfactory impairments
  • No history of psychiatric disorders

Exclusion criteria

Exclusion Criteria:

  • Communication difficulties
  • Unwilling to participate
  • Using other herbal or aromatherapy treatments
  • History of sleep disorders affecting sleep quality (e.g., obstructive sleep apnea)
  • Secondary hypertension or other chronic diseases
  • Pregnant or breastfeeding
  • Use of tobacco products
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    experimental group

    Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) in addition to routine care for primary hypertension. Anxiety, sleep quality, and blood pressure are assessed before and after the intervention.

    Other: Lavender

  • No intervention
    Routine care only

    Participants in the control group continue their routine care and treatment for primary hypertension without receiving lavender oil inhalation. Anxiety, sleep quality, and blood pressure are assessed before and after the study period.

Interventions

  • OtherLavender

    Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardized diffuser. This intervention is provided in addition to routine care for primary hypertension. Outcomes measured include anxiety, sleep quality, and blood pressure before and after the intervention.

06

What researchers measure

Primary outcomes

  1. Anxiety

    Measured using the Beck Anxiety Inventory (BAI) at baseline, week 2, and week 4. Higher scores indicate higher anxiety.

    Time frame: Baseline, Week 2, Week 4

  2. Blood Pressure

    Measured using the Hypertension Diagnostic Form at baseline, week 2, and week 4. Includes systolic and diastolic measurements.

    Time frame: Baseline, Week 2, Week 4

Secondary outcomes

  1. Sleep quality

    Measured using the Pittsburgh Sleep Quality Index (PSQI) at baseline, week 2, and week 4. Higher scores indicate poorer sleep quality

    Time frame: Baseline, Week 2, Week 4

07

Study locations

1 of 1 sites recruiting
  • Ardahan State Hospital
    Ardahan, Ardahan 75000, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to confidentiality and privacy concerns of study participants.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Oct 2025, 3 months after the start.

Of 70 non-industry interventional studies with no phase under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's planned 3 months is below that.

Counting every sponsor, half of 80 studies reached it within 20 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 25, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Oct 9, 2025
CompletionEst.
Oct 9, 2025
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192783
Lead sponsor
Ardahan University
Responsible party
Derya Şimşekli (Asist. Prof. Dr., Ardahan University) — Principal investigator
First posted
Sep 25, 2025
Start date
Jul 7, 2025
Primary completion
Oct 9, 2025 (estimated)
Completion
Oct 9, 2025 (estimated)
Last update
Sep 25, 2025

Study contacts

Derya ŞİMŞEKLİ, PhD
Contact
deryasimsekli@ardahan.edu.tr
+905545965789

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion